Arcus Biosciences Net Income
| RCUS Stock | USD 21.13 0.10 0.48% |
As of the 9th of February, Arcus Biosciences shows the mean deviation of 2.74, and Risk Adjusted Performance of 0.0342. In respect to fundamental indicators, the technical analysis model gives you tools to check existing technical drivers of Arcus Biosciences, as well as the relationship between them. Please confirm Arcus Biosciences mean deviation, information ratio, as well as the relationship between the Information Ratio and downside variance to decide if Arcus Biosciences is priced correctly, providing market reflects its regular price of 21.13 per share. Given that Arcus Biosciences has jensen alpha of 0.0831, we suggest you to validate Arcus Biosciences's prevailing market performance to make sure the company can sustain itself at a future point.
Arcus Biosciences Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 7.8417 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -255.6 M | -242.8 M | |
| Net Loss | -240.3 M | -228.3 M | |
| Net Loss | -254.7 M | -242 M | |
| Net Loss | (3.61) | (3.79) | |
| Net Income Per E B T | 0.92 | 0.80 |
Arcus | Net Income | Build AI portfolio with Arcus Stock |
The evolution of Net Income for Arcus Biosciences provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Arcus Biosciences compares to historical norms and industry peers.
Latest Arcus Biosciences' Net Income Growth Pattern
Below is the plot of the Net Income of Arcus Biosciences over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Arcus Biosciences financial statement analysis. It represents the amount of money remaining after all of Arcus Biosciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Arcus Biosciences' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Arcus Biosciences' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (283 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Arcus Net Income Regression Statistics
| Arithmetic Mean | (101,650,706) | |
| Geometric Mean | 58,582,312 | |
| Coefficient Of Variation | (116.56) | |
| Mean Deviation | 101,971,855 | |
| Median | (49,594,000) | |
| Standard Deviation | 118,487,514 | |
| Sample Variance | 14039.3T | |
| Range | 360M | |
| R-Value | (0.78) | |
| Mean Square Error | 5782.8T | |
| R-Squared | 0.61 | |
| Significance | 0.0002 | |
| Slope | (18,383,625) | |
| Total Sum of Squares | 224628.7T |
Arcus Net Income History
Other Fundumenentals of Arcus Biosciences
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Arcus Biosciences Net Income component correlations
Arcus Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Arcus Biosciences is extremely important. It helps to project a fair market value of Arcus Stock properly, considering its historical fundamentals such as Net Income. Since Arcus Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Arcus Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Arcus Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will Arcus introduce new products? Factors like these will boost the valuation of Arcus Biosciences. Anticipated expansion of Arcus directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Arcus Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.42) | Revenue Per Share | Quarterly Revenue Growth (0.46) | Return On Assets | Return On Equity |
Arcus Biosciences's market price often diverges from its book value, the accounting figure shown on Arcus's balance sheet. Smart investors calculate Arcus Biosciences' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Since Arcus Biosciences' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Arcus Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Arcus Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Arcus Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Arcus Biosciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Arcus Biosciences' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Arcus Biosciences.
| 11/11/2025 |
| 02/09/2026 |
If you would invest 0.00 in Arcus Biosciences on November 11, 2025 and sell it all today you would earn a total of 0.00 from holding Arcus Biosciences or generate 0.0% return on investment in Arcus Biosciences over 90 days. Arcus Biosciences is related to or competes with Immunitybio, Denali Therapeutics, Galapagos, Cogent Biosciences, Agios Pharm, Viridian Therapeutics, and Beam Therapeutics. Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the... More
Arcus Biosciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Arcus Biosciences' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Arcus Biosciences upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.65 | |||
| Information Ratio | 0.0098 | |||
| Maximum Drawdown | 19.63 | |||
| Value At Risk | (6.53) | |||
| Potential Upside | 5.64 |
Arcus Biosciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Arcus Biosciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Arcus Biosciences' standard deviation. In reality, there are many statistical measures that can use Arcus Biosciences historical prices to predict the future Arcus Biosciences' volatility.| Risk Adjusted Performance | 0.0342 | |||
| Jensen Alpha | 0.0831 | |||
| Total Risk Alpha | (0.27) | |||
| Sortino Ratio | 0.0082 | |||
| Treynor Ratio | 0.2694 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Arcus Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Arcus Biosciences February 9, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0342 | |||
| Market Risk Adjusted Performance | 0.2794 | |||
| Mean Deviation | 2.74 | |||
| Semi Deviation | 4.4 | |||
| Downside Deviation | 4.65 | |||
| Coefficient Of Variation | 3070.22 | |||
| Standard Deviation | 3.93 | |||
| Variance | 15.44 | |||
| Information Ratio | 0.0098 | |||
| Jensen Alpha | 0.0831 | |||
| Total Risk Alpha | (0.27) | |||
| Sortino Ratio | 0.0082 | |||
| Treynor Ratio | 0.2694 | |||
| Maximum Drawdown | 19.63 | |||
| Value At Risk | (6.53) | |||
| Potential Upside | 5.64 | |||
| Downside Variance | 21.65 | |||
| Semi Variance | 19.35 | |||
| Expected Short fall | (2.64) | |||
| Skewness | (1.00) | |||
| Kurtosis | 2.72 |
Arcus Biosciences Backtested Returns
Currently, Arcus Biosciences is not too volatile. Arcus Biosciences secures Sharpe Ratio (or Efficiency) of 0.0347, which signifies that the company had a 0.0347 % return per unit of standard deviation over the last 3 months. We have found twenty-nine technical indicators for Arcus Biosciences, which you can use to evaluate the volatility of the firm. Please confirm Arcus Biosciences' mean deviation of 2.74, and Risk Adjusted Performance of 0.0342 to double-check if the risk estimate we provide is consistent with the expected return of 0.14%. Arcus Biosciences has a performance score of 2 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.44, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Arcus Biosciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Arcus Biosciences is expected to be smaller as well. Arcus Biosciences right now shows a risk of 4.0%. Please confirm Arcus Biosciences downside variance, and the relationship between the total risk alpha and daily balance of power , to decide if Arcus Biosciences will be following its price patterns.
Auto-correlation | 0.00 |
No correlation between past and present
Arcus Biosciences has no correlation between past and present. Overlapping area represents the amount of predictability between Arcus Biosciences time series from 11th of November 2025 to 26th of December 2025 and 26th of December 2025 to 9th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Arcus Biosciences price movement. The serial correlation of 0.0 indicates that just 0.0% of current Arcus Biosciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | -0.26 | |
| Residual Average | 0.0 | |
| Price Variance | 1.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Arcus Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Arcus Biosciences reported net income of (283 Million). This is 182.92% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 149.56% higher than that of the company.
Arcus Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Arcus Biosciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Arcus Biosciences could also be used in its relative valuation, which is a method of valuing Arcus Biosciences by comparing valuation metrics of similar companies.Arcus Biosciences is currently under evaluation in net income category among its peers.
Arcus Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Arcus Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Arcus Biosciences' managers, analysts, and investors.Environmental | Governance | Social |
Arcus Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Arcus Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Arcus Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Arcus Biosciences' value.| Shares | Bnp Paribas Investment Partners Sa | 2025-06-30 | 1.4 M | Sofinnova Ventures | 2025-06-30 | 1.2 M | Ra Capital Management, Llc | 2025-06-30 | 1.1 M | Wellington Management Company Llp | 2025-06-30 | 936 K | Jacobs Levy Equity Management, Inc. | 2025-06-30 | 805.3 K | Millennium Management Llc | 2025-06-30 | 780.1 K | Charles Schwab Investment Management Inc | 2025-06-30 | 776.7 K | Northern Trust Corp | 2025-06-30 | 691.2 K | Goldman Sachs Group Inc | 2025-06-30 | 648.1 K | Blackrock Inc | 2025-06-30 | 11.5 M | Vanguard Group Inc | 2025-06-30 | 6.6 M |
Arcus Fundamentals
| Return On Equity | -0.68 | ||||
| Return On Asset | -0.21 | ||||
| Profit Margin | (1.42) % | ||||
| Operating Margin | (5.46) % | ||||
| Current Valuation | 1.88 B | ||||
| Shares Outstanding | 123.73 M | ||||
| Shares Owned By Insiders | 30.09 % | ||||
| Shares Owned By Institutions | 60.75 % | ||||
| Number Of Shares Shorted | 8.9 M | ||||
| Price To Earning | 27.69 X | ||||
| Price To Book | 5.97 X | ||||
| Price To Sales | 10.84 X | ||||
| Revenue | 258 M | ||||
| Gross Profit | (263 M) | ||||
| EBITDA | (269 M) | ||||
| Net Income | (283 M) | ||||
| Cash And Equivalents | 1.05 B | ||||
| Cash Per Share | 14.48 X | ||||
| Total Debt | 60 M | ||||
| Debt To Equity | 0.17 % | ||||
| Current Ratio | 6.22 X | ||||
| Book Value Per Share | 4.07 X | ||||
| Cash Flow From Operations | (170 M) | ||||
| Short Ratio | 4.84 X | ||||
| Earnings Per Share | (3.42) X | ||||
| Target Price | 33.0 | ||||
| Number Of Employees | 627 | ||||
| Beta | 0.84 | ||||
| Market Capitalization | 2.6 B | ||||
| Total Asset | 1.15 B | ||||
| Retained Earnings | (1.13 B) | ||||
| Working Capital | 790 M | ||||
| Net Asset | 1.15 B |
About Arcus Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Arcus Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arcus Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arcus Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcus Stock Analysis
When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.